The DOI matches its Crossref record; 418 of the 418 references it cites were found in a registry or an index.
Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches
Open accessAbstract
Pulmonary fibrosis is a chronic progressive lung disease that steadily leads to lung architecture disruption and respiratory failure. The development of pulmonary fibrosis is mostly the result of previous acute lung inflammation, caused by a wide variety of etiological factors, not resolved over time and causing the deposition of fibrotic tissue in the lungs. Despite a long history of study and good coverage of the problem in the scientific literature, the effective therapeutic approaches for pulmonary fibrosis treatment are currently lacking. Thus, the study of the molecular mechanisms underlying the transition from acute lung inflammation to pulmonary fibrosis, and the search for new molecular markers and promising therapeutic targets to prevent pulmonary fibrosis development, remain highly relevant tasks. This review focuses on the etiology, pathogenesis, morphological characteristics and outcomes of acute lung inflammation as a precursor of pulmonary fibrosis; the pathomorphological changes in the lungs during fibrosis development; the known molecular mechanisms and key players of the signaling pathways mediating acute lung inflammation and pulmonary fibrosis, as well as the characteristics of the most common in vivo models of these processes. Moreover, the prognostic markers of acute lung injury severity and pulmonary fibrosis development as well as approved and potential therapeutic approaches suppressing the transition from acute lung inflammation to fibrosis are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–418 of 418
Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
Odackal, J., Yu, V., Gomez-Manjerres, D., Field, J. J., Burdick, M. D., & Mehrad, B. (2020) · ERJ Open Research · doi:10.1183/23120541.00481-2020 · Cited by 16
Suresh, M. V., Yalamanchili, G., Rao, T. C., Aktay, S. L., Kralovich, A., Shah, Y. M., & Raghavendran, K. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00132 · Cited by 16
Existing and emerging treatments for idiopathic pulmonary fibrosis
Kolilekas, L., Papiris, S. A., & Bouros, D. E. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568244 · Cited by 15
van Oort, P. M. P., Bos, L. D. J., Póvoa, P. M. S. R., Ramírez, P., Torres, A., Artigas, A., Schultz, M. J., & Martín‐Loeches, I. (2019) · ERJ Open Research · doi:10.1183/23120541.00212-2018 · Cited by 15
A Damaged-Informed Lung Ventilator Model for Ventilator Waveforms
Agrawal, D. K., Smith, B. J., Sottile, P. D., & Albers, D. J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.724046 · Cited by 15
Statins’ still controversial role in pulmonary fibrosis: What does the evidence show?
Andreikos, D., Karampitsakos, Τ., Tzouvelekis, A., & Stratakos, G. K. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102168 · Cited by 15
Piotrowski, W. J., Martusewicz-Boros, M. M., Białas, A. J., Barczyk, A., Batko, B. P., Błasińska, K., Boros, P. W., Górska, K., Grzanka, P., Jassem, E., et al. (2022) · Advances in respiratory medicine · doi:10.3390/arm90050052 · Cited by 15
Puntorieri, V., Hiansen, J. Q., McCaig, L., et al. (2013) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-13-67 · Cited by 14
Xu, W., Xu, B., Zhao, Y., Yang, N., Liu, C., Wen, G., & Zhang, B. (2015) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-015-0446-4 · Cited by 14
Association of ADAM17 Expression Levels in Patients with Interstitial Lung Disease
Ge, J., Tang, L., Mu, P., Zhu, F., Xie, L. N., & Tang, Y. (2019) · Immunological Investigations · doi:10.1080/08820139.2019.1660367 · Cited by 13
Reddy, C. A., & Wakwaya, Y. T. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000841 · Cited by 13
Stevens, N. C., Edwards, P. C., Tran, L. M., Ding, X., Winkle, L. S. V., & Fiehn, O. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab110 · Cited by 12
Zhang, H., Dong, W., Li, S., Zhang, Y., Zhou, L., Yang, L., Jiang, L., Wu, T., & Wang, Y. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1967409 · Cited by 12
Intermittent hyperbaric oxygen exposure mobilizing peroxiredoxin 6 to prevent oxygen toxicity
Zhang, L., Zhang, Y., Zhongzhuang, W., Chen, Y., & Li, R. (2019) · The Journal of Physiological Sciences · doi:10.1007/s12576-019-00694-5 · Cited by 11
Post-COVID-19 respiratory problems: burden and management
Kessler, A., Heightman, M., & Brennan, E. (2022) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000619 · Cited by 10
Baran, M. T. (2020) · Colorectal Disease · doi:10.1111/codi.15311 · Cited by 9
Arai, T., Hirose, M., Kagawa, T., Hatsuda, K., & Inoue, Y. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1418 · Cited by 9
Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
Wu, X., Kaner, R. J., & Martínez, F. J. (2017) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-0041 · Cited by 1
Cited by
Yan, J., Wang, S.-Y., Su, Q., Zou, M.-W., Zhou, Z.-Y., Shou, J., & Huo, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59093-7 · Cited by 62
Zeyada, M. S., Eraky, S. M., & El-Shishtawy, M. M. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122272 · Cited by 31
Metadata
- Authors
- Savin, I. A., Zenkova, M. A., & Sen’kova, A. V.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-29
- Volume
- 23
- Issue
- 23
- Pages
- 14959
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4311040528
- Cited by
- 279
- References
- 418
- FWCI
- 29.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.